| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | M H Moghadasian | |
| J J Frohlich | |||
| P2860 | cites work | Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia | Q28334603 |
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells | Q30871041 | ||
| Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors | Q33742346 | ||
| Current perspectives on statins | Q33818381 | ||
| Low-density lipoprotein-independent effects of statins | Q33841088 | ||
| HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients | Q33864528 | ||
| Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q34409983 | ||
| Perspective. How many women have osteoporosis? | Q35437028 | ||
| Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis | Q37372546 | ||
| HMG-CoA reductase inhibitors and the risk of fractures | Q38496425 | ||
| Stimulation of bone formation in vitro and in rodents by statins | Q40914337 | ||
| Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. | Q42543174 | ||
| Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering | Q43516483 | ||
| Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators | Q43988923 | ||
| Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy. | Q51250458 | ||
| Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase | Q73212125 | ||
| HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients | Q73924094 | ||
| Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women | Q73958010 | ||
| Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study | Q74152546 | ||
| Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial | Q77362332 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 803-805 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Canadian Medical Association Journal | Q5030320 |
| P1476 | title | Statins and bones | |
| P478 | volume | 164 |
| Q34991463 | Statins and menopause | cites work | P2860 |
Search more.